Filing Summary
Registrant and period: The filing is a Form 8-K filed by Priveterra Acquisition Corp. on August 19, 2022. Although the request metadata identifies AEON Biopharma, Inc., the filing text identifies Priveterra Acquisition Corp. as the registrant.
Business Context and Reporting Period
Priveterra Acquisition Corp. is a special purpose acquisition company. The filing addresses a correction to its Second Amended and Restated Certificate of Incorporation, originally filed on February 8, 2021.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Change
On August 19, 2022, the company filed a Certificate of Correction with the Delaware Secretary of State. The correction fixes a scrivener’s error in the charter by changing the deadline for completing the company’s initial business combination from 18 months to 24 months. The correction is retroactively effective as of February 8, 2021.
Outlook, Risks, and Unusual Items
The filing does not provide financial guidance or management commentary. The principal unusual item is the retroactive correction of the SPAC’s business-combination deadline. The filing does not state the revised specific calendar deadline beyond the 24-month period.
Investor Verification Items
- Verify that the correct registrant is Priveterra Acquisition Corp., not AEON Biopharma, Inc.
- Review Exhibit 3.1 for the complete text and operative terms of the Certificate of Correction.
- Confirm the applicable 24-month business-combination deadline and any related extension provisions.
- Assess the company’s status as a SPAC, including its ability to complete a business combination within the corrected timeframe.